Keypoints
- The World Health Organization (WHO) is updating its clinical guidelines to combat the global opioid crisis, which accounts for 450,000 of the 600,000 drug-related deaths annually.
- New recommendations include the use of long-acting injectable buprenorphine as a treatment option for opioid dependence.
- Despite 64 million people worldwide living with drug use disorders, fewer than 10 percent currently have access to treatment.
- The full updated guidelines, focusing on evidence-based care and community overdose management, are expected to be published between late 2026 and early 2027.
Main Story
The World Health Organization (WHO) has announced a significant update to its forthcoming guidelines for treating opioid dependence and managing community overdoses.
In a statement released Monday, the organization reported that opioids remain the primary driver of drug-related morbidity and mortality globally.
Data from 2023 indicates that out of 316 million drug users worldwide, approximately 61 million engaged in non-medical opioid use, leading to a staggering 450,000 deaths.
To address the massive treatment gap where 90 percent of those with drug use disorders receive no care, the WHO is expanding its recommendations for Opioid Agonist Maintenance Treatment (OAMT).
While continuing to endorse methadone and oral buprenorphine, the updated guidance now includes long-acting injectable buprenorphine as a conditional recommendation. These updates were informed by a rigorous review process by the Guideline Development Group (GDG), which balanced clinical benefits against costs, equity, and feasibility.
The Issues
The core issue identified by the WHO is the lack of accessible, ethical, and high-quality care for those at risk. The “treatment gap” remains a critical barrier to reducing the global death toll. Furthermore, the organization noted that the drug-related health burden is disproportionately high for opioid users compared to users of other substances. By introducing long-acting injectables into the formal framework, the WHO seeks to solve adherence challenges often associated with daily oral medications, providing more flexible options for patients in diverse economic settings.
What’s Being Said
- “Opioids continue to account for the largest share of the drug-related health burden, including fatal overdose,” the WHO stated in its report.
- The organization emphasized that “ensuring that people with opioid dependence… have access to affordable, ethical, high-quality and evidence-based support and care is essential.”
- Regarding the new treatment options, WHO reaffirms its support for OAMT but now “extends its guidance to include new formulations of long-acting injectable buprenorphine.”
- The statement noted that the rigorous development process considered “the balance of benefits and harms, values and preferences, cost-effectiveness, equity, acceptability and feasibility.”
What’s Next
- The WHO Steering Group is currently finalizing the peer-review process for the full document.
- Publication of the comprehensive guidelines, including implementation strategies and identified research gaps, is slated for late 2026 or early 2027.
- Health ministries globally are expected to use these evidence profiles to update their national drug policies and expand community-based overdose response programs.
Bottom Line
With hundreds of thousands of lives lost annually to opioids, the WHO’s move to modernize treatment protocols and include long-acting medications represents a vital step toward closing the global treatment gap and making life-saving care more accessible.
%20has%20announced%20a%20significant%20update%20to%20its%20forthcoming%20guidelines%20for%20treating%20opioid%20...){kind=link}